https://doi.org/10.4081/reumatismo.2020.1267
Different fracture risk profile in patients treated with anti-osteoporotic drugs in real-life
Accepted: 15 April 2020
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
In this retrospective study, we intended to investigate the baseline fracture risk profile in patients who started treatment with different anti-osteoporotic medications. We analyzed retrospectively the fracture risk calculated with DeFRA, a validated FRAX derived tool, in women who started an anti-osteoporotic treatment from 2010 to 2017. We analyzed baseline data of 12,024 post-menopausal women aged over 50 years. Teriparatide initiators had a baseline 10-year risk of major osteoporotic fracture of 82.1% with a Standard Deviation (SD) of 66.5%. Denosumab initiators and zoledronic acid initiators had a greater 10-year baseline risk of fracture (54.3%, SD 46.5% and 47.0%, SD 42.0 respectively) than patients initiated on alendronate (24.9%, SD 34.6%) and patients initiated on risedronate (23.9%, SD 24.1%). Using DeFRA, a FRAX™ derived tool, we showed significantly different fracture risk profiles in women who were started on various therapeutic agents for the treatment of osteoporosis in routine clinical practice.
How to Cite
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- M. Sebastiani, A. Manfredi, M. Colaci, D. Giuggioli, R. La Sala, N. Elkhaldi, A. Antonelli, C. Ferri, Correlation of a quantitative videocapillaroscopic score with the development of digital skin ulcers in scleroderma patients , Reumatismo: Vol. 60 No. 3 (2008)
- F. Schiavon, M. Favero, V. Carraro, L. Riato, Septic arthritis: what is the role for the rheumatologist? , Reumatismo: Vol. 60 No. 1 (2008)
- A.R. Carone, S. D'Amore, L. Albanese, F. Craig, P. Scagliusi, M. D'Amore, Hospital anxiety and depression , Reumatismo: Vol. 59 No. 4 (2007)
- M. Cutolo, M. Olivieri, M.E. Secchi, M.A. Cimino, Therapy of rheumatic polymyalgia: the pathophysiologic management , Reumatismo: Vol. 59 No. 4 (2007)
- F. Atzeni, P. Sarzi-Puttini, Do we have markers to define the cardiovascular risk in rheumatoid arthritis patients? , Reumatismo: Vol. 61 No. 1 (2009)
- M. Cardoso de Souza, R. Trajano Jorge, A. Jones, I. Lombardi Júnior, J. Natour, Progressive resistance training in patients with shoulder impingement syndrome: literature review , Reumatismo: Vol. 61 No. 2 (2009)
- M. Turiel, S. Sitia, L. Tomasoni, S. Cicala, F. Atzeni, L. Gianturco, M. Longhi, V. De Gennaro Colonna, P. Sarzi-Puttini, Cardiac involvement in rheumatoid arthritis , Reumatismo: Vol. 61 No. 4 (2009)
- Irene Pontikaki, Valeria Gerloni, Maurizio Gattinara, Alfredomaria Lurati, Alessandra Salmaso, Gabriele De Marco, Barbara Teruzzi, Elisabetta Valcamonica, Flavio Fantini, Side effects of anti-TNFa therapy in juvenile idiopathic arthritis , Reumatismo: Vol. 58 No. 1 (2006)
- M. Parodi, L. Bensi, T. Maio, G.S. Mela, M.A. Cimmino, Comorbidities in rheumatoid arthritis: analysis of hospital discharge records , Reumatismo: Vol. 57 No. 3 (2005)
- P. Ostuni, M.E.C. Battista, A. Furlan, Efficacy of Carbopol 974P (Siccafluid) in the treatment of severe to moderate keratoconjunctivitis sicca (KCS) in patients with primary Sjögren’s syndrome (SS) not responding to standard treatment with artificial tears , Reumatismo: Vol. 57 No. 2 (2005)
<< < 7 8 9 10 11 12 13 14 15 16 > >>
You may also start an advanced similarity search for this article.
